Staburo supports research on the impact of coronavirus disease on methodological aspects of ongoing clinical trials

On behalf of Staburo, Josef Höfler and our former colleague Nicole Krämer submitted comments on the EMA’s draft guidance on “Points to consider on implications of Coronavirus disease (COVID-19) on methodological aspects of ongoing clinical trials”.

The guidance, set up by the Biostatistics Working Party, covers actions that sponsors of ongoing clinical trials affected by the coronavirus disease (COVID-19) pandemic should take to help ensure the integrity of their studies and interpretation of study results while safeguarding the safety of trial participants as a first priority.